GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiMed Biologics Inc (ROCO:4147) » Definitions » Cyclically Adjusted PS Ratio

TaiMed Biologics (ROCO:4147) Cyclically Adjusted PS Ratio : 47.39 (As of May. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is TaiMed Biologics Cyclically Adjusted PS Ratio?

As of today (2024-05-26), TaiMed Biologics's current share price is NT$87.20. TaiMed Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$1.84. TaiMed Biologics's Cyclically Adjusted PS Ratio for today is 47.39.

The historical rank and industry rank for TaiMed Biologics's Cyclically Adjusted PS Ratio or its related term are showing as below:

ROCO:4147' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 33.44   Med: 45.92   Max: 75.22
Current: 47.46

During the past years, TaiMed Biologics's highest Cyclically Adjusted PS Ratio was 75.22. The lowest was 33.44. And the median was 45.92.

ROCO:4147's Cyclically Adjusted PS Ratio is ranked worse than
91.9% of 506 companies
in the Biotechnology industry
Industry Median: 5.565 vs ROCO:4147: 47.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TaiMed Biologics's adjusted revenue per share data for the three months ended in Mar. 2024 was NT$0.706. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$1.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


TaiMed Biologics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for TaiMed Biologics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiMed Biologics Cyclically Adjusted PS Ratio Chart

TaiMed Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 45.69 40.83 45.58

TaiMed Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.98 60.44 49.56 45.58 47.79

Competitive Comparison of TaiMed Biologics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, TaiMed Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiMed Biologics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiMed Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TaiMed Biologics's Cyclically Adjusted PS Ratio falls into.



TaiMed Biologics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

TaiMed Biologics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=87.20/1.84
=47.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, TaiMed Biologics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.706/131.7762*131.7762
=0.706

Current CPI (Mar. 2024) = 131.7762.

TaiMed Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.001 100.470 0.001
201606 0.002 101.688 0.003
201609 0.003 101.861 0.004
201612 0.002 101.863 0.003
201703 0.005 102.862 0.006
201706 0.010 103.349 0.013
201709 0.010 104.136 0.013
201712 0.009 104.011 0.011
201803 0.000 105.290 0.000
201806 0.149 106.317 0.185
201809 0.344 106.507 0.426
201812 0.450 105.998 0.559
201903 0.503 107.251 0.618
201906 0.605 108.070 0.738
201909 0.828 108.329 1.007
201912 0.815 108.420 0.991
202003 0.935 108.902 1.131
202006 0.696 108.767 0.843
202009 0.579 109.815 0.695
202012 0.595 109.897 0.713
202103 0.357 111.754 0.421
202106 0.601 114.631 0.691
202109 0.358 115.734 0.408
202112 0.296 117.630 0.332
202203 0.159 121.301 0.173
202206 0.387 125.017 0.408
202209 0.370 125.227 0.389
202212 1.275 125.222 1.342
202303 0.280 127.348 0.290
202306 0.408 128.729 0.418
202309 0.528 129.860 0.536
202312 0.616 129.419 0.627
202403 0.706 131.776 0.706

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TaiMed Biologics  (ROCO:4147) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


TaiMed Biologics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of TaiMed Biologics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiMed Biologics (ROCO:4147) Business Description

Traded in Other Exchanges
N/A
Address
No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others.

TaiMed Biologics (ROCO:4147) Headlines

No Headlines